Knapp Katherine, Ignoffo Robert
Touro University California College of Pharmacy, Vallejo, CA 94592, USA.
Pharmacy (Basel). 2020 Mar 18;8(1):43. doi: 10.3390/pharmacy8010043.
Based on the projected need for a larger oncology care workforce, we estimated the patient care visits and care activities that Board Certified oncology pharmacists (BCOPs) could contribute to oncology care from 2020-2025. Using projected counts for BCOPs through 2025, we estimated that 2.9-4.1 million 30-min BCOP patient visits were possible at 50% workforce capacity. BCOPs' clinical activities overlapped strongly with those of nurse practitioners (NPs) and physician assistants (PAs) in patient education and treatment management. BCOPs could help reduce provider stress and burnout concerns by spreading these activities across a broader set of providers. BCOPs were more active than NPs and PAs in clinical trials research. Recent advances in immunotherapy, pharmacogenetics, pharmacogenomics, and oral oncolytic agents make the medication-focused training of OPs particularly useful to care teams. Comparison also showed that BCOPs were less active in providing follow-up visits and prescribing. Fulfilling the projected BCOP numbers through 2025 will require continued growth in Postgraduate Year 2 (PGY2) oncology pharmacy resident programs and on-the-job training programs. Our review of the trends in cancer incidence, mortality, and survivorship suggest a sustained need for the activities of BCOPs and other oncology care providers.
基于对更大规模肿瘤护理劳动力的预计需求，我们估算了2020年至2025年期间，获得委员会认证的肿瘤药师（BCOP）可为肿瘤护理贡献的患者护理就诊次数及护理活动。利用到2025年BCOP的预计数量，我们估算出，在劳动力容量达到50%的情况下，可能会有290万至410万次由BCOP进行的30分钟患者就诊。在患者教育和治疗管理方面，BCOP的临床活动与执业护士（NP）和医师助理（PA）的临床活动有很大重叠。BCOP可以通过将这些活动分散到更广泛的医疗人员群体中，帮助减轻医疗人员的压力和职业倦怠问题。BCOP在临床试验研究方面比NP和PA更为活跃。免疫疗法、药物遗传学、药物基因组学和口服溶瘤药物的最新进展，使得针对肿瘤药师的以药物为重点的培训对护理团队尤为有用。比较还显示，BCOP在进行随访和开处方方面的活跃度较低。要实现到2025年的BCOP预计数量，将需要继续增加肿瘤药学住院医师第二年（PGY2）培训项目和在职培训项目。我们对癌症发病率、死亡率和生存率趋势的审查表明，持续需要BCOP和其他肿瘤护理人员开展相关活动。
